Immunovant, Inc.
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
IMVT | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 320 WEST 37TH STREET, 10018 NEW YORK
- Website:
- https://immunovant.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Immunovant, Inc. is a clinical-stage immunology company dedicated to developing innovative therapies for people with autoimmune diseases. The company focuses on advancing a pipeline of novel, FcRn-targeted therapies, including monoclonal antibodies, designed to address the complex and variable needs of patients across different disease stages and severities. Through a patient-centric approach, Immunovant aims to develop treatments that enable individuals with autoimmune conditions to live normal lives. The company is a subsidiary of Roivant Sciences Ltd.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immunovant, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immunovant, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immunovant, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
